MIT-based Spinoff Sigilon Therapeutics Raises $80.3m Series B to Advance “Shielded Living Therapeutics” to Clinical Trials

MIT-based Spinoff Sigilon Therapeutics Raises $80.3m Series B to Advance “Shielded Living Therapeutics” to Clinical Trials

Sigilon Therapeutics, Inc., a biotechnology company developing cures for patients with chronic diseases through its Shielded Living Therapeutics Platform, announced it completed a $80.3 million Series B financing. This money will be put to use supporting the...

Pin It on Pinterest